DexCom, Inc. (DXCM) Net Income CAGR:73.91%(TTM)
The net income cagr for DexCom, Inc. (DXCM) is +73.91% over the latest trailing 12-month period. Net income CAGR uses precomputed financial statement history.
The net income cagr for DexCom, Inc. (DXCM) stock is 73.91% over the past 12 months. The 3 year average growth rate is 47.05% and the 5 year cagr is 12.60%. Net income CAGR shows how DexCom, Inc.'s bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
DXCM Net Income CAGR Chart
DexCom, Inc. (DXCM)
DXCM Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $576.20M | $836.30M | +$260.10M | +45.14% | +45.14% |
| 2024 | $541.50M | $576.20M | +$34.70M | +6.41% | +6.41% |
| 2023 | $341.20M | $541.50M | +$200.30M | +58.70% | +58.70% |
| 2022 | $216.90M | $341.20M | +$124.30M | +57.31% | +57.31% |
| 2021 | $493.60M | $216.90M | $-276.70M | -56.06% | -56.06% |
| 2020 | $101.10M | $493.60M | +$392.50M | +388.23% | +388.23% |
| 2019 | $-127.10M | $101.10M | +$228.20M | +0.00% | N/A |
| 2018 | $-50.20M | $-127.10M | $-76.90M | +0.00% | N/A |
| 2017 | $-65.60M | $-50.20M | +$15.40M | +0.00% | N/A |
| 2016 | $-57.60M | $-65.60M | $-8.00M | +0.00% | N/A |
| 2015 | $-22.40M | $-57.60M | $-35.20M | +0.00% | N/A |
| 2014 | $-29.80M | $-22.40M | +$7.40M | +0.00% | N/A |
| 2013 | $-54.50M | $-29.80M | +$24.70M | +0.00% | N/A |
| 2012 | $-44.75M | $-54.50M | $-9.75M | +0.00% | N/A |
| 2011 | $-55.17M | $-44.75M | +$10.42M | +0.00% | N/A |
| 2010 | $-53.52M | $-55.17M | $-1.65M | +0.00% | N/A |
| 2009 | $-55.18M | $-53.52M | +$1.66M | +0.00% | N/A |
| 2008 | $-45.88M | $-55.18M | $-9.31M | +0.00% | N/A |
| 2007 | $-46.60M | $-45.88M | +$721.29K | +0.00% | N/A |
| 2006 | $-30.77M | $-46.60M | $-15.83M | +0.00% | N/A |
| 2005 | $-13.95M | $-30.77M | $-16.82M | +0.00% | N/A |
| 2004 | $-9.91M | $-13.95M | $-4.03M | +0.00% | N/A |
| 2003 | $-7.71M | $-9.91M | $-2.21M | +0.00% | N/A |
| 2002 | $-6.27M | $-7.71M | $-1.44M | +0.00% | N/A |
| 2001 | $-3.96M | $-6.27M | $-2.31M | +0.00% | N/A |
Quarterly Net Income — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $199.50M | -25.4% | +89.3% |
| Q4 2025 | $267.30M | -5.8% | +76.2% |
| Q3 2025 | $283.80M | +57.8% | +110.8% |
| Q2 2025 | $179.80M | +70.6% | +25.3% |
| Q1 2025 | $105.40M | -30.5% | -28.0% |
| Q4 2024 | $151.70M | +12.7% | -40.8% |
| Q3 2024 | $134.60M | -6.2% | +11.5% |
| Q2 2024 | $143.50M | -2.0% | +23.8% |
| Q1 2024 | $146.40M | -42.9% | +201.2% |
| Q4 2023 | $256.30M | +112.3% | +179.2% |
| Q3 2023 | $120.70M | +4.1% | +19.3% |
| Q2 2023 | $115.90M | +138.5% | +127.7% |
| Q1 2023 | $48.60M | -47.1% | -50.1% |
| Q4 2022 | $91.80M | -9.3% | +573.2% |
| Q3 2022 | $101.20M | +98.8% | +42.7% |
| Q2 2022 | $50.90M | -47.7% | -19.1% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach